This single-center cross-sectional retrospective chart review sought to define the prevalence of neuropsychiatric (NP) disorders among children with non-alcoholic fatty liver disease (NAFLD) compared to the general population. The prevalence rate of NP disorders was determined at diagnosis among children evaluated from 2006 to 2016. The NP disorder prevalence rates were compared to those reported in the 2016 National Survey of Children’s Health (NSCH). 24.3% of 254 children with NAFLD reported to have at least 1 NP disorder compared to 16.9% of those in NSCH (relative risk [RR] = 1.44; P < .0001). More children had intellectual disability (ID) (4.5% vs 0.8%; RR = 5.43, P < .0001), depression (3.9% vs 2.2%; RR = 1.82, P = .0009), or autism spectrum disorder (ASD) (3.3% vs 2.0%; RR = 1.67, P = .047) in the Boston Children’s Hospital (BCH) NAFLD cohort. The prevalence of 1 NP disorder was 29.4% in our cohort compared to 22.3% in NSCH (RR = 1.32; P = .007). Children with NAFLD have a higher rate of NP disorders compared to the general population.
SchwimmerJBDeutschRKahenTLavineJEStanleyCBehlingC.Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388-93. doi:10.1542/peds.2006-1212.
2.
AndersonELHoweLDJonesHEHigginsJPLawlorDAFraserA.The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE. 2015;10(10):e0140908. doi:10.1371/journal.pone.0140908.
KimDYooERLiAA, et al. Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther. 2019;50(5):590-598. doi:10.1111/apt.15395.
5.
JungJYParkSKOhCMChungPWRyooJH.Non-alcoholic fatty liver disease and its association with depression in Korean general population. J Korean Med Sci. 2019;34(30):e199. doi:10.3346/jkms.2019.34.e199.
6.
YoussefNAAbdelmalekMFBinksM, et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33(7):1062-1070. doi:10.1111/liv.12165.
7.
MouzakiMYodoshiTArce-ClacharAC, et al. Psychotropic medications are associated with increased liver disease severity in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2019;69(3):339-343. doi:10.1097/MPG.0000000000002401.
8.
KistlerKDMollestonJUnalpAAbramsSHBehlingCSchwimmerJB.Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31(3):396-406. doi:10.1111/j.1365-2036.2009.04181.x.
9.
ShedlockKSusiAGormanGHHisle-GormanEErdie-LalenaCRNylundCM.Autism spectrum disorders and metabolic complications of obesity. J Pediatr. 2016;178:183-187. doi:10.1016/j.jpeds.2016.07.055.
10.
KimEJKwonHJHaM, et al. Relationship among attention-deficit hyperactivity disorder, dietary behaviours and obesity. Child Care Health Dev. 2014;40(5):698-705. doi:10.1111/cch.12129.
11.
LeeCKJonasMM.High prevalence of psychiatric and attention-deficit/ hyperactivity disorders in children with NAFLD at Children’s Hospital Boston 1995-2005: a retrospective study. Paper presented at the Digestive Diseases Week; May 14, 2007; Washington, DC.
12.
NoonSD’AnnibaleDSchwimmerM, et al. Incidence of depression and anxiety in a cohort of adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2021;72(4):579-583. doi:10.1097/mpg.0000000000003024.
13.
HarrisPATaylorRMinorBL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208.
14.
HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG.Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010.
15.
American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
16.
National Survey of Children’s Health. Child and family health measures, national performance and outcome measures, and subgroups, [format eg. SAS/SPSS/Stata] codebook, version [insert version], data resource center for child and adolescent health supporte.2016. https://www.childhealthdata.org
17.
SpiegelmanDHertzmarkE.Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199-200. doi:10.1093/aje/kwi188.
18.
CoburnSRoseMSadyM, et al. Mental health disorders and psychosocial distress in pediatric celiac disease. J Pediatr Gastroenterol Nutr. 2020;70(5):608-614. doi:10.1097/mpg.0000000000002605.
19.
SheinbeinDHSteinRIHayesJF, et al. Factors associated with depression and anxiety symptoms among children seeking treatment for obesity: a social-ecological approach. Pediatr Obes. 2019;14(8):e12518. doi:10.1111/ijpo.12518.
20.
HockRKinsmanAOrtagliaA.Examining treatment adherence among parents of children with autism spectrum disorder. Disabil Health J. 2015;8(3):407-413. doi:10.1016/j.dhjo.2014.10.005.
21.
SchaeferMRWagonerSTYoungME, et al. Subjective versus objective measures of medication adherence in adolescents/young adults with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2019;40(1):54-59. doi:10.1097/DBP.0000000000000602.
22.
AlkhouriNSedkiEAlisiA, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013;33(1):79-85. doi:10.1111/liv.12024.
23.
LeeCKMitchellPDRazaRHarneySWigginsSMJonasMM.Validation of transient elastography cut points to assess advanced liver fibrosis in children and young adults: the Boston children’s hospital experience. J Pediatr. 2018;198:84-89. doi:10.1016/j.jpeds.2018.02.062.
